CARDIAC ARRHYTHMIA SUPPRESSION TRIAL

心律失常抑制试验

• 批准号: 3647516
• 负责人: ROBERT C. SCHLANT
• 金额: $ 0.28万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-08-15 至 1992-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3647516
• 关键词: antiarrhythmic agent; cardiotonic agents; cardiovascular disorder epidemiology; clinical trials; cooperative study; drug adverse effect; heart disorder chemotherapy; human mortality; human subject; human therapy evaluation; myocardial infarction; premature ventricular contractions; sudden cardiac death; ventricular fibrillation; antiarrhythmic agent; cardiotonic agents; cardiovascular disorder epidemiology; clinical trials; cooperative study; drug adverse effect; heart disorder chemotherapy; human mortality; human subject; human therapy evaluation; myocardial infarction; premature ventricular contractions; sudden cardiac death; ventricular fibrillation

This contractor will be a clinical center for the collaborative clinical trial, Cardiac Arrhythmia Treatment Study (CATS). The primary objective of this contract is to see if effective drug treatment of frequent ventricular premature depolarizations in post-myocardial infarction patients will reduce the incidence of sudden cardiac death; secondary objectives are to (1) assess the impact of treatment on all-cause mortality, (2) evaluate adverse drug effects, (3) examine the clinical course of the disease in the control group, and (4) conduct selected substudies to clarify the disease process and the mechanisms of drug efficacy. A three-year recruitment period is designed, following a ten-month planning phase. Follow-up will continue two years beyond patient recruitment.

该承包商将成为协作临床的临床中心 试验，心律失常治疗研究（CATS）。 主要目标 该合同是要查看频繁心室的有效药物治疗 腰椎后梗塞患者的过度去极化 减少心脏猝死的发生率；次要目标是 （1）评估治疗对全因死亡率的影响，（2）评估 不良药物影响，（3）检查该疾病的临床过程 对照组，（4）进行选定的取代以阐明该疾病 过程和药物功效的机制。 为期三年的招聘 经过十个月的计划阶段，设计时期。 后续意志 在患者招募之外继续两年。